Literature DB >> 20607313

Awake intubation under sedation using target-controlled infusion of dexmedetomidine: five case reports.

Takayuki Kunisawa1, Michio Nagashima, Satoshi Hanada, Akihiro Suzuki, Osamu Takahata, Hiroshi Iwasaki.   

Abstract

We used target-controlled infusion (TCI) of dexmedetomidine (DEX) for awake intubation under sedation in 5 patients who had a risk of pulmonary aspiration or difficult airway. Dexmedetomidine level was escalated stepwise until the patients developed tolerance to laryngoscopy. The target DEX concentrations at the time of intubation were 2.10-5.95 ng/ml and were higher than those clinically used for sedation in the intensive care unit (ICU). Chin lift was applied in 1 case, and therefore no assisted ventilation was required and pulse oxygen saturation was maintained at >98% throughout the procedure. Simple pharmacological interventions for blood pressure changes induced by increased target plasma DEX concentrations were needed in 4 cases. However, hemodynamics was stable, and no cardiovascular drug was needed after tracheal intubation. Conditions at laryngoscopy were excellent in all cases, and conditions at tracheal intubation were good except in 1 case. Reflex to intubation was preserved in all cases, and coughing was observed in all cases. The patients had no memory of discomfort and/or intubation. Although further investigations are needed, this method may be useful for awake intubation under sedation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20607313     DOI: 10.1007/s00540-010-0980-8

Source DB:  PubMed          Journal:  J Anesth        ISSN: 0913-8668            Impact factor:   2.078


  8 in total

Review 1.  Clinical uses of alpha2 -adrenergic agonists.

Authors:  T Kamibayashi; M Maze
Journal:  Anesthesiology       Date:  2000-11       Impact factor: 7.892

2.  Dexmedetomidine as a total intravenous anesthetic agent.

Authors:  Michael A E Ramsay; David L Luterman
Journal:  Anesthesiology       Date:  2004-09       Impact factor: 7.892

3.  The dose of succinylcholine required for excellent endotracheal intubating conditions.

Authors:  Mohamed Naguib; Abdulhamid H Samarkandi; Mansour Emad El-Din; Khaled Abdullah; Mazen Khaled; Saleh W Alharby
Journal:  Anesth Analg       Date:  2006-01       Impact factor: 5.108

4.  Assessment of the sedative effects of dexmedetomidine, an alpha 2-adrenoceptor agonist, with analysis of saccadic eye movements.

Authors:  R Aantaa
Journal:  Pharmacol Toxicol       Date:  1991-05

5.  The effects of increasing plasma concentrations of dexmedetomidine in humans.

Authors:  T J Ebert; J E Hall; J A Barney; T D Uhrich; M D Colinco
Journal:  Anesthesiology       Date:  2000-08       Impact factor: 7.892

6.  Controlled sedation with alphaxalone-alphadolone.

Authors:  M A Ramsay; T M Savege; B R Simpson; R Goodwin
Journal:  Br Med J       Date:  1974-06-22

7.  Dexmedetomidine infusion for sedation during fiberoptic intubation: a report of three cases.

Authors:  Stuart A Grant; Dara S Breslin; David B MacLeod; David Gleason; Gavin Martin
Journal:  J Clin Anesth       Date:  2004-03       Impact factor: 9.452

8.  Computer-controlled infusion of intravenous dexmedetomidine hydrochloride in adult human volunteers.

Authors:  J B Dyck; M Maze; C Haack; D L Azarnoff; L Vuorilehto; S L Shafer
Journal:  Anesthesiology       Date:  1993-05       Impact factor: 7.892

  8 in total
  7 in total

1.  The effect of dexmedetomidine on arterial-cardiac baroreflex function assessed by spectral and transfer function analysis.

Authors:  Toru Ehara; Yojiro Ogawa; Jitsu Kato; Ken Aoki; Setsuro Ogawa; Ken-ichi Iwasaki
Journal:  J Anesth       Date:  2012-03-02       Impact factor: 2.078

2.  Successful management of difficult airway in an adult patient of Goldenhar syndrome.

Authors:  Neeru Sahni; Nidhi Bhatia
Journal:  Saudi J Anaesth       Date:  2014-11

3.  The dexmedetomidine concentration required after remifentanil anesthesia is three-fold higher than that after fentanyl anesthesia or that for general sedation in the ICU.

Authors:  Takayuki Kunisawa; Kazuhiro Fujimoto; Atsushi Kurosawa; Michio Nagashima; Koji Matsui; Dai Hayashi; Kunihiko Yamamoto; Yuya Goto; Hiroaki Akutsu; Hiroshi Iwasaki
Journal:  Ther Clin Risk Manag       Date:  2014-10-04       Impact factor: 2.423

4.  Attenuation of sympathoadrenal responses and anesthetic requirement by dexmedetomidine.

Authors:  Arpita Laha; Sarmila Ghosh; Susanta Sarkar
Journal:  Anesth Essays Res       Date:  2013 Jan-Apr

5.  Dexmedetomidine versus remifentanil for sedation during awake intubation using a Shikani optical stylet: a randomized, double-blinded, controlled trial.

Authors:  Ting Xu; Min Li; Cheng Ni; Xiang-Yang Guo
Journal:  BMC Anesthesiol       Date:  2016-08-02       Impact factor: 2.217

6.  Dexmedetomidine-based intravenous anesthesia of a pediatric patient with glucose-6-phosphate dehydrogenase (G6PD) deficiency: A case report.

Authors:  Nanae Takahashi; Takashi Ogawa; Zen'ichiro Wajima; Akibumi Omi
Journal:  Medicine (Baltimore)       Date:  2017-05       Impact factor: 1.889

7.  A systematic review and meta-analysis of the safety and efficacy of remifentanil and dexmedetomidine for awake fiberoptic endoscope intubation.

Authors:  Zhi-Hang Tang; Qi Chen; Xia Wang; Nan Su; Zhengyuan Xia; Yong Wang; Wu-Hua Ma
Journal:  Medicine (Baltimore)       Date:  2021-04-09       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.